SNTA Stock Quote

SNTA Press Releases, Recent News

• Monday, June 03, 2013 10:37 AM EST
  What's Next: Synta Pharmaceuticals Corp, Affymax Inc, Tesla Motors Inc, AT&T Inc
  Openglobe - Jun 3, 2013

  Synta Pharmaceuticals Corp.(NASDAQ:SNTA) shares fell 31.71% to $5.04. The company, on June 3, announced results from an interim survival analysis of the GALAXY-1 trial, a global, randomized, multi-center Phase 2b/3 study designed to evaluate the ...

  SYNTA PHARMACEUTICALS CORP. : Synta Announces Positive Overall ... - 4-traders (press release)
  Synta Pharmaceuticals Corp. (NASDAQ:SNTA) trend analysis, Peregrine ... - NIS
  
• Friday, June 07, 2013 9:59 AM EST
  Hot Movers: Christopher & Banks Corporation, Gafisa SA (ADR), Synta ...
  Openglobe - Jun 7, 2013

  Christopher & Banks Corporation (NYSE:CBK) stock gained 6.88% to $7.25. The company on June 6 said its first-quarter net income was $0.63 million or $0.02 per share, compared to net loss of $13.41 million or $0.38 per share in the prior-year quarter.
• Monday, June 10, 2013 10:35 AM EST
  Clovis Oncology Inc (CLVS), Synta Pharmaceuticals Corp. (SNTA): Post-ASCO ...
  Insider Monkey (blog) - Jun 10, 2013

  Synta Pharmaceuticals Corp. (NASDAQ:SNTA) presented Phase 2 data for its lung-cancer drug ganetespip. In premarket trading, the stock was trading higher by more than 8% in response to data.
• Friday, May 31, 2013 3:08 PM EST
  SYNTA PHARMACEUTICALS CORP. : Synta to Host Investor Meeting and ...
  4-traders (press release) - May 31, 2013

  Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will host an investor meeting and webcast to discuss interim results from the GALAXY-1 trial, a randomized Phase 2b/3 study designed to evaluate ganetespib in combination ...
• Friday, June 14, 2013 3:48 PM EST
  Technical Bull Stock Alert: Synta Pharmaceuticals Corp. (SNTA)
  SBWire (press release) - Jun 14, 2013

  Bridgewater, MA -- (SBWIRE) -- 06/14/2013 -- The online StockConsultant latest screen has found a biotech company that developes novel drug products for extending and enhancing the lives for patients with cancer and chronic inflammatory disease Synta ...
• Tuesday, June 04, 2013 5:21 PM EST
  Synta Pharmaceuticals Corp. - Special Call
  Seeking Alpha - Jun 4, 2013

  Synta Pharmaceuticals Corp. (SNTA) Investor Meeting and Webcast at the 2013 ASCO Annual Meeting June 3, 2013 8:00 PM ET. Safi R. Bahcall.

  Synta Shares Fall on Study of Lung-Cancer Drug - Moneynews
  
• Friday, June 07, 2013 8:11 AM EST
  NASDAQ MARKET MOVERS: Comtech Telecomm. Corp., Concurrent Computer ...
  SBWire (press release) - Jun 7, 2013

  Huntington Beach, CA -- (SBWIRE) -- 06/07/2013 -- PSPicks.com provides its subscribers with a free newsletter that reports up to the minute information and exclusive charts on cheap, undervalued, hidden, and undiscovered stocks traded on the NASDAQ, ...
• Friday, June 07, 2013 5:25 AM EST
  Synta Pharmaceuticals Corp . ( NASDAQ : SNTA ) reports results for GALAXY – 1
  NIS - Jun 7, 2013

  Synta Pharmaceuticals Corp. (NASDAQ:SNTA), a bio pharmaceutical company with primary focus on the development and commercialization of small molecule drugs for the treatment of medical conditions in patients with cancer and other inflammatory ...

  MLV Capital Lowers Synta Pharmaceuticals Price Target to $16.00 (SNTA) - Mideast Time
  Update on Corporate Activities in Stock Market (SNTA, BV, RST, VNDA) - SBWire (press release)
  
• Friday, June 07, 2013 11:40 AM EST
  In Insider Trading, Biopharma Companies Synta Pharmaceuticals and Epizyme ...
  Minyanville.com - Jun 7, 2013

  Bruce Kovner, a Director of biopharmaceutical company Synta Pharmaceuticals Corp. (NASDAQ:SNTA), bought 2 million shares of the cancer and inflammatory diseases drug company stock for $9,270,354.
• Sunday, June 09, 2013 6:16 AM EST
  5 of Last Week's Biggest Losers
  Motley Fool - Jun 9, 2013

  Let's start with Synta Pharmaceuticals. Shares shed more than a third of their value after disappointing results for the biotech's experimental lung cancer treatment.